Teva propofol plant closing followed jury award for hep C outbreak

Generics-maker Teva ($TEVA) ceased propofol production three weeks after a jury awarded $500 million to school principal Henry Chanin in May 2010. Chanin contracted hepatitis C during a procedure in which he was administered the anesthetic, acknowledged VP Craig Lea yesterday in a Las Vegas court. He was under examination by attorney Robert Eglet. According to a release issued by law concern Mainor Eglet, "public outcry" prompted the shutdown.

Current proceedings involve the case of Anne Arnold, who also contracted the disease. The release says a contaminated jumbo 50-milliliter infusion vial of the anesthesia was reused during a colonoscopy procedure at the Endoscopy Center of Southern Nevada in 2007. The jumbo vial is intended for long-term sedation, not for short-duration procedures such as colonoscopies.

The trial involves Teva, as well as drug distributors Baxter International ($BAX) and McKesson ($MCK). Eglet said they knew sales of large vials of the drug could help spread blood-borne diseases.

Teva faces almost 300 lawsuits from the hepatitis C outbreak, which appears to be traced to the Endoscopy Center. The defendants contend that misuse of the single-use propofol vials by medical providers caused the outbreak. A state grand jury indicted Dipak Desai, who ran the Endoscopy Center during the outbreak; he's been found incompetent to stand trial.

The voluntary facility shutdown led to the termination of 70 of several hundred employees, Teva Pharmaceuticals spokeswoman Denise Bradley told us a year ago. The company contends it exited the propofol business because the drug is hard to make and is barely profitable, as reported.

- see the release
- and this Bloomberg story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.